Milnacipran efficacy in the prevention of recurrent depression: A 12-month placebo-controlled study

International Clinical Psychopharmacology

Volumn 15, Issue 3, 2000, Pages 133-140

  Rouillon, F ^a   Warner, B ^a   Pezous, N ^a   Bisserbe, J C ^a   Agussol, P ^a   Alaix, C ^a   Alary, P ^a   Autheman, B ^a   Azra, R ^a   Barbier, D ^a   Baudrillard, C ^a   Bellot, J C ^a   Benssoussan, M ^a   Bensussan, P ^a   Berdah, C S ^a   Bessuges, J M ^a   Billion, A ^a   Blanchard, C ^a   Blauwblomme, J F ^a   Bonnafoux, D ^a   Bornstein, S ^a   Bouadjera, P ^a   Boubli, S ^a   Bourg, M ^a   Braconnier, A ^a   Brousse, A M ^a   Burnat, G ^a   Capdeville, Ch ^a   Capdeville, Cl ^a   Cardot, H ^a   Carrier, C G ^a   Cayssials, P ^a   Charbaut, J ^a   Chelias, A ^a   Clerc, G ^a   Conraux, ^a   Costeja, J M ^a   Cournac, P ^a   Cyran, S ^a   Dabert Bourasset, M ^a   Danan, A ^a   Danic, M ^a   Daurignac, M ^a   De Nuce De Lamothe, P ^a   Degrais, D ^a   Demant, J C ^a   Demogeot, C ^a   Depierre, C ^a   Deyrieux, B ^a   Dumon, P H ^a   Dumont, P ^a   Dussartre, J ^a   Emery, B ^a   Estrabol, ^a   Fabiani, J M ^a   Faruch, M ^a   Ferrey, G ^a   Fonvieille, V ^a   Fuseau, Y ^a   Gandois, F ^a   Gaubert, R ^a   Gaussares, C ^a   Gillard, M H ^a   Giraud D'Elloy, E ^a   Gozlan, G ^a   Grimaud, B ^a   Grivois, H ^a   Guibert, M ^a   Guilloux, J ^a   Hakim, ^a   Hanus, M ^a   Haumonte, M T ^a   Henry, E ^a   Hirigoyen, M F ^a   Jammes, P ^a   Kalck, M ^a   Kurc, H ^a   Lanvin, F ^a   Laqueille, X ^a   Lavaud, J L ^a   Le Goues, G ^a   Leclercq, P ^a   Lefebvre, P ^a   Legoubey, P ^a   Lermuzeaux, C ^a   Lhoste, ^a   Liegaut, D ^a   Lombertie, E R ^a   Mabillon, M ^a   Magnan, M ^a   Maloux, H ^a   Maquet, D ^a   Marcou, G ^a   Marmin, P ^a   Marro, G ^a   Mathieru, P ^a   May, J P ^a   Meaux, J P ^a   Mella, P ^a   more..

^a Hopital Albert Chenevier   (France)

Author keywords

Milnacipran; Unipolar depression

Indexed keywords

MILNACIPRAN;

ABDOMINAL PAIN; ADULT; AGED; ANXIETY NEUROSIS; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RECURRENT DISEASE; VERTIGO;

EID: 0034085152     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200015030-00002     Document Type: Article

References (45)

1. AHRCP (1993) Depression in Primary Care: Vol. 2. Treatment of Major Depression. Rockville, MD: US Department of Health and Human Services, Agency for Health Care Policy and Research.
2. American Psychiatric Association (1982) Diagnostic and Statistical Manual of Mental Disorders, 3rd edn. Washington, DC: American Psychiatric Association.
3. Angst J (1990) Natural history and epidemiology of depression. In: Current Approaches (Cobb J, Goeting N, eds), Southampton: Duphar Medical Relations. pp. 1-11.
4. Angst J (1992) How recurrent and predictable is depressive illness? In: Long-Term Treatment of Depression (Montgomery SA, Rouillon F, eds), New York: John Wiley and Son. pp. 1-13.
5. Barr L, Goodman W, Price L (1994) Physical symptoms associated with paroxetine discontinuation. Am J Psychiatry 151:289.
6. Cox DR, Oakes D (1984) Analysis of Survival Data. London: Chapman and Hall.
7. Doogan DP, Caillard V (1992) Sertraline in the prevention of depression. Br J Psychiatry 160:217-222.
8. Fawcett J (1993) The morbidity and mortality of clinical depression. Int Clin Psychopharmacol 8:217-220.
9. Fleming T, Harrington D (1991) Counting Processes and Survival Analysis. New York: John Wiley and Son.
10. Franchini L, Gasperini M, Perez J, Smeraldi E, Zanardi R (1997) A double-blind study of long-term treatment with sertraline or fluvoxamine for prevention of highly recurrent unipolar depression. J Clin Psychiatry 58:104-107.
11. Frank E, Kupfer DJ, Perel JM, Cleon C, Jarret DB, Mallinger AG, et al. (1990) Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 47:1093-1099.
12. Frank E, Prien R, Jarrett R, Keller M, Kupfer D, Lavori P, et al. (1991) Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Arch Gen Psychiatry 48:851-855.
13. Georgotas A, McCue RE, Cooper TB (1989) A placebo-controlled comparison of nortriptyline and phenelzine in maintenance therapy of elderly depressed patients. Arch Gen Psychiatry 46:783-786.
14. Glen AIM, Johnson AL, Shepherd M (1984) Continuation therapy with lithium and amitriptyline in unipolar depressive illness: a randomized double-blind controlled trial. Psychol Med 14:37-50.
15. Greenhouse JB, Stangl D, Kupfer DJ, Prien RF (1991) Methodologic issues in maintenance therapy clinical trials. Arch Gen Psychiatry 48:313-318.
16. Greist J, Jefferson JW, Kobak KA, Katzelnick DJ (1995) Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. Arch Gen Psychiatry 52:53-60.
17. Guelfi JD, Lancrenon S, Pédarriosse AM, Amrein R, Stabl M (1994) Recent clinical developments with reversible and selective monoamine oxidase inhibitors - long-term prophylactic effect of moclobemide in patients with recurrent major depression (DSM-III-R). Neuropsychopharmacology 10 (Suppl 3):416S.
18. Guy W (1976) ECDEU - Assessment Manual for Psychopharmacology. Washington, DC: National Institute of Mental Health.
19. Guze S, Robins E (1970) Suicide and primary affective disorders. Br J Psychiatry 117:437-438.
20. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
21. Kasper S, Plétan Y, Solles A, Tournoux A (1996) Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: a summary of clinical trial results. Int Clin Psychopharmacol 11 (Suppl 4):35-39.
22. Keller MB, Herman GL, Lavori PW, Coryell W, Endicott J, Taylor J (1984) Long-term outcome of episodes of major depression: clinical and public health significance. JAMA 252:788-792.
23. Keller MB, Lavori P, Mueller T, Endicott J, Coryell W, Hirschfelf R, Shea T (1992) Time to recovery, chronicity, and levels of psychopathology in major depression. Arch Gen Psychiatry 49:809-816.
24. Kupfer DJ (1991) Long-term treatment of depression. J Clin Psychiatry 52:28-34.
25. Kupfer DJ, Frank E, Perel JM, Cornes C, Mallinger A, Thase M, et al. (1992) Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry 49:769-773.
26. Lopez-Ibor J, Guelfi JD, Plétan Y, Tournoux A, Prost JF (1996) Milnacipran and selective serotonin reuptabke inhibitors in major depression. Int Clin Psychopharmacol 11 (Suppl 4):41-46.
27. Macher JP, Sichel JP, Serre C, Von Frenckell R, Huck JC, Demarez JP (1989) A double-blind placebo controlled study of milnacipran in hospitalized patients with major depressive disorders. Neuropsychobiology 22:77-82.
28. Maj M, Veltro F, Pirozzi R, Lobrace S, Magliano L (1992) Pattern of recurrence of illness after recovery from an episode of major depression: a prospective study. Am J Psychiatry 149:6.
29. Montgomery SA (1989) Prophylaxis in recurrent unipolar depression: a new indication for treatment studies. J Psychopharmacol 3:47-53.
30. Montgomery SA, Dunbar G (1993) Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. Int Clin Psychopharmacol 8:189-195.
31. Montgomery SA, Dufour H, Brion S, Gailledreau J, Laqueille X, Ferrey G, et al. (1988) The prophylactic efficacy of fluoxetine in unipolar depression. Br J Psychiatry 153 (Suppl):69-76.
32. Montgomery SA, Doogan DP, Burnside R (1991) The influence of different relapse criteria on the assessment of long-term efficacy of sertraline. Int Clin Psychopharmacol 6 (Suppl):37-40.
33. Montgomery SA, Rasmussen JGC, Tanghøj P (1993) A 24-week study of 20mg citalopram, 40mg citalopram, and placebo in the prevention of relapse of major depressive disorder. Int Clin Psychopharmacol 8:181-88.
34. Montgomery SA, Reimitz P-E, Zivkov M (1998) Mirtazapine versus amitriptyline in the long-term treatment of depression: a double-blind placebo-controlled study. Int Clin Psychopharmacol 13:63-73.
35. Moret C, Chaveron M, Finberg JPM, Couzinier JP, Briley M (1985) Biochemical profile of milnacipran (F2207), a potential fourth generation antidepressant drug. Neuropharmacology 24:1211-1219.
36. NIMH-NIH Consensus Development Conference Statement (1985) Mood disorders: prevention of recurrence. Am J Psychiatry 1442:469-472.
37. Paykel ES, Ramana R, Cooper Z, Hayhurst H, Kerr J, Barocka A (1995) Residual symptoms after partial remission: an important outcome in depression. Psychol Med 25:1171-1180.
38. Prien RF, Kupfer DJ, Mansky PA, Smal JG, Tuason VB, Voss CB, Johnson WE (1984) Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Report of the NIMH Collaborative Study group. Arch Gen Psychiatry 41:1096-1104.
39. Prien RF, Kupfer DJ (1986) Continuation drug therapy for major depressive episodes: how long should it be maintained. Am J Psychiatry 143:18-23.
40. Prien RF, Kocsis JH (1995) Long-term treatment of mood disorders. The fourth generation in progress. In: Psychopharmacology (Bloom F, Kupfer D, eds), New York: Raven Press. pp. 1067-1079.
41. Ramana R, Paykel ES, Cooper Z, Hayhurst H, Saxty M, Surtees PG (1995) Remission and relapse in major depression: a two-year prospective follow-up study. Psychol Med 25:1161-1170.
42. Robinson DS, Lerfald SC, Bennett B, Laux D, Devereaux E, Kayser A, et al. (1991) Continuation and maintenance treatment of major depression with the monoamine oxidase inhibitor phenelzine: a double-blind placebo-controlled discussion study. Psychopharmacol Bull 27:31-39.
43. Surtess P, Barkley C (1994) Future imperfect: the long term outcome of depression. Br J Psychiatry 164: 327-341.
44. Terra JL, Montgomery SA (1998) Fluvoxamine prevents recurrence of depression: results of a long-term, double-blind, placebo-controlled study. Int Clin Psychopharmacol 13:55-62.
45. World Health Organization Mental Health Collaborating Centers (1989) Pharmacotherapy of depressive disorders: a consensus statement. J Affect Dis 17:197-198.